Silence Therapeutics plc Increase (Decrease) in Accounts Receivable
Silence Therapeutics plc (SLNCF) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-10
- Silence Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Silence Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $0.00.
- Silence Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$30.00K, a 104.91% decline year-over-year.
- Silence Therapeutics plc increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$62.00K.
- Silence Therapeutics plc increase (decrease) in accounts receivable for fiscal 2025 was -$1.02M, a 213.27% decline from fiscal 2024.
- Silence Therapeutics plc increase (decrease) in accounts receivable for fiscal 2024 was $904.00K.
- Silence Therapeutics plc increase (decrease) in accounts receivable for fiscal 2023 was -$392.00K, a 154.22% decline from fiscal 2022.
- Silence Therapeutics plc increase (decrease) in accounts receivable for fiscal 2022 was $723.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | -$30.00K derived: sum of 3 quarters · filed 2026-08-10 | -$92.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | -$30.00K derived: sum of 2 quarters · filed 2026-05-07 | -$92.00K derived: sum of 3 quarters · filed 2026-05-07 | -$84.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$92.00K derived: sum of 2 quarters · filed 2026-03-05 | -$84.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.02M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$54.00K derived: sum of 2 quarters · filed 2026-08-10 | -$994.00K 10-Q · filed 2025-11-06 | -$383.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$932.00K 10-Q · filed 2026-08-10 | -$321.00K derived: sum of 3 quarters · filed 2026-08-10 | -$2.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$940.00K 10-Q · filed 2026-05-07 | -$329.00K derived: sum of 2 quarters · filed 2026-05-07 | -$2.08M derived: sum of 3 quarters · filed 2026-05-07 | -$10.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $611.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.14M derived: sum of 2 quarters · filed 2026-03-05 | -$9.11M derived: sum of 3 quarters · filed 2026-03-05 | $904.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$9.72M derived: sum of 2 quarters · filed 2025-11-06 | $293.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$7.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.04M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $10.01M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$392.00K 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $723.00K 10-K · filed 2025-02-27 |